Medtronic Debuts at China Chain Expo, Showcasing Local Co-Creation Through Innovative Medical Technologies
Medtronic
Medical Device Manufacturer
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
Heart Future
July 16, 2025The 3rd China International Supply Chain Promotion Expo(hereinafter referred to as the "China Chain Expo") opened at the China National Convention Center in Beijing. Medtronic, as a global leading medical technology enterprise, participated for the first time, systematically showcasing its strategic upgrade path over 36 years of deep cultivation in China, from product implementation to ecosystem collaboration.
This exhibition,Medtronic showcasedMedical Innovation Chain, Local Intelligence Manufacturing Chain, Value Co-creation Chain, Intelligent Service Chain, and Collaborative Supply-Win ChainFive Pillars: Reflecting the Accelerated Transformation from "Innovative Technology Provider" to "Local Ecosystem Co-builder"These three innovative achievements collectively demonstrate how enterprises can promote global resource integration and systematic innovation under the guidance of local demand in China.
# Three Core Products Unveiled
At the Chain Expo, Medtronic showcased three innovative products from different clinical fields as representative achievements of its "China Value Chain" strategy, systematically illustrating the implementation path from technology development to ecosystem collaboration.
These three products focus respectively onCardiac Rhythm Management, Hypertension Intervention, and Structural Heart Valve DiseaseThree Major High-Incidence Disease Fields: Including the Lantern Catheter, a treatment concept pioneered by Chinese doctors that has become a global standard consensus; the RDN System, which was the first to achieve simultaneous market launches in China, the US, and Europe, offering an alternative pathway for hypertension management; and the Evolut FX+ Transcatheter Aortic Valve System, representing the cutting-edge of interventional structural heart disease treatments and designed for lifelong patient management. Below are detailed introductions of the three products:
Lantern Left Bundle Branch Pacing (LBBP) Cardiac Delivery Catheter
Lantern Left Bundle Branch Pacing (LBBP) Cardiac Delivery Catheter Debuts as a Representative Achievement of "Medtronic’s Integration of Medical and Engineering Expertise, Local Innovation, Giving Back to the World".
Technical ValueIn 2017, Medtronic collaborated with Chinese clinicians to discover the left bundle branch pacing site consistent with the heart's natural electrical conduction sequence, initiating exploration of related therapies; currently, most of the early global clinical evidence for left bundle branch pacing comes from China, where this therapy originated.Has been incorporated into international pacing treatment consensus and guidelines, becoming a new paradigm for arrhythmia treatment.。
Clinical Significance: Relying on the advantages of China's medical-industrial collaboration and local supply chain, the Medtronic China R&D Center and local clinical experts have deeply collaborated to jointly develop the product Lantern, which is suitable for this innovative therapy. This is alsoMedtronicThe First ProductHeart Pacemaker Catheter Products: Made in China, Serving the World。
Symplicity Spyral RDN System
Innovation Points：The World's FirstInterventional RDN Treatment System Approved for Entry into the Chinese, U.S., and EU Markets。
Technical Value：The system uses radiofrequency energy to thermally ablate the sympathetic nerves surrounding the renal arteries through a vascular intervention approach, thereby reducing blood pressure.Long-term, all-day antihypertensive efficacy can be achieved through a single treatment., isCurrent Hypertension Treatment Methods - Supplementary Lifestyle Interventions and Antihypertensive Drug Therapy。
Clinical Significance: The Symplicity Spyral RDN system, as a revolutionary technology for the treatment of hypertension with medical devices, was the first to enter the special clinical application in Hainan Boao Lecheng Pilot Zone in 2021. At the same time, it initiated the clinical verification and exploration of RDN technology in China's real-world setting in 2022. With the policy support from the Lecheng Pilot Zone and the promotion through multi-party cooperation, the system officially received approval from the National Medical Products Administration for marketing in 2024.The world's first hypertension interventional treatment device system to receive approval for marketing in the three major regions of the United States, the European Union, and China., offering a new treatment option for patients in China with refractory hypertension and those who are intolerant to medication.
Evolut FX+ Transcatheter Aortic Valve Replacement System
This is a TAVR (Transcatheter Aortic Valve Replacement) system designed for the treatment of aortic valve stenosis, offering advantages such as minimally invasive intervention, rapid postoperative recovery, and lifelong management support. It represents a cutting-edge platform in the field of structural heart disease interventional therapy.
Innovation Points：Medtronic's Latest Generation TAVR Platform Globally, with a Valve Frame Design Featuring a 4-Times Larger Viewing Window(Large Commissure Window), significantly enhancing future compatibility with coronary intervention (PCI).
Technical ValueCompared with traditional open-heart surgery, TAVR is a minimally invasive therapy that completes aortic valve replacement through a catheter, offering advantages such as minimal trauma, quick recovery, and improved postoperative quality of life. Evolut FX+ inherits the core advantages of the Evolut platform, including its self-expanding design and low-profile deployment.At the same time, through structural optimization, larger windows are set on the valve frame to improve the spatial compatibility for postoperative coronary re-access.. This design is dedicated to meeting the long-term postoperative management needs of patients with aortic valve stenosis, and it is strategically significant for elderly patients and those with concomitant coronary artery disease.
Clinical Significance: Evolut FX+ received FDA approval in April 2024 and is the latest generation TAVR product from Medtronic to date, representing the cutting-edge advancement in transcatheter valve implantation technology. In China, the Evolut series quickly entered clinical use after receiving approval in 2021. To date, it has been implemented in over 150 medical institutions, fostering the development of structural heart disease interventional diagnosis and treatment teams centered on TAVR across various regions in China, promoting the standard upgrade for treating valvular diseases in elderly patients.
# Continuous Deepening of Local Value Chain Strategy, Five Chains Collaborating to Build a Closed-loop Medical Technology Ecosystem
Against the backdrop where industrial chain stability and innovation synergy are increasingly becoming the focus of national strategy, Medtronic comprehensively explained its "local full value chain" strategy at this year's Chain Expo. It proposed to build a localized ecological network covering R&D, production, clinical trials, collaboration, and services, supported by five synergistic chains. This layout not only responds to the trend of local strategic upgrades for global medical companies "from market to system," but also provides a demonstration path for the integration of medical industry and innovation chains.
Medical Innovation Integration Chain：Driven by clinical needs in China, Medtronic continuously promotes the collaborative innovation of local medicine and engineering.The birth of the Lantern catheter is a typical practice where Chinese doctors first proposed the concept of left bundle branch pacing, which was then jointly developed and transformed by enterprises, and eventually gave back to the global market. In recent years, Medtronic has also continued to promote the rapid approval and clinical adoption of localized products in fields such as neurointervention and rhythm management in China, such as the Medtronic Axium Coils, further shortening the path from discovery to market in China.
Local Manufacturing Chain：Relying on multiple nodes such as Changzhou Kanghui Science and Technology Park, Kangdi Integrated Surgical Base, and Medtronic Shanghai Factory, the company has preliminarily built up a "Smart Manufacturing + Export" system centered around China.Taking the "Genesis Electric吻" as an example, which achieved 100% local R&D design in China by 2024, the product took only one year from project initiation to mass production. It has already covered over 500 hospitals across China and has been exported to international markets, becoming a diversified complement in the field of surgical electric staplers.
Value Co-creation Chain：Facing new technology challenges in areas such as chronic disease management and surgical innovation, Medtronic is establishing a therapy validation and market transformation platform centered in China through mechanisms like the Boao Lecheng Pilot Zone and real-world research.Since the Symplicity Spyral RDN system began its pilot program in Lecheng in 2021, it has completed multicenter clinical exploration in China's real-world setting and received regulatory approval in China in 2024, becoming the world’s first RDN interventional treatment device to gain approval in China, the United States, and Europe.
Intelligent Service Chain：By introducing technologies such as artificial intelligence, digital twins, and structural simulation, Medtronic is upgrading the management of complex diseases from "surgical optimization" to a "digital closed-loop."Starting with structural cardiovascular disease as the entry point, Medtronic is expanding its intelligent service chain. For instance, it is developing integrated follow-up, remote management, and coronary re-intervention support solutions around the Evolut FX+ platform to help valve disease patients achieve a closed-loop pathway for long-term postoperative monitoring and retreatment compatibility.
Collaborative Supply Chain for Win-Win: Currently,Medtronic has established approximately7,000Local supply chain partners have formed a highly collaborative manufacturing network in China.Among them, nearly 90% of indirect procurement is provided by local enterprises in China, and some core components and systems have been directly serving overseas factories. In areas such as green logistics, digital warehousing, and quality collaboration, Medtronic works with its supplier partners to implement the ESG system, helping local enterprises accelerate their integration into the global medical supply chain.
From the localization of products to the co-construction and co-research of platforms, Medtronic's "local value chain" strategy is not only an upgrade of its localization in the Chinese market, but also a redefinition of the collaborative innovation system in medical technology from a global perspective.
# Executive Insights: The Chain Expo is a platform for co-building and sharing; Medtronic will create the future together with its Chinese counterparts
Mr. Yu-Shao Gu, Global Senior Vice President of Medtronic and President of Greater ChinaSaid: "Thank you to the Chain Expo platform for providing opportunities for openness, exchange, and cooperation. Medtronic firmly believes that China will become the largest medical market globally and an important source of innovation, playing an increasingly significant role in the global medical industry chain. Promoting collaboration and mutual progress is key to driving medical innovation to benefit patients worldwide. Medtronic will continue to strengthen its local value chain presence with the goal of mutual growth and shared success. We look forward to partnering with more industry players to promote the stability and long-term development of the medical technology industry supply chain, building a global health community and benefiting patients around the world."
# About Medtronic
Medtronic (NYSE: MDT) is a global leader in medical technology, dedicated to improving human health through innovative technologies. The company's core businesses span cardiovascular health, surgical solutions, and neuroscience, with over 90,000 employees worldwide. Guided by its mission to "alleviate pain, restore health, and extend life," Medtronic continues to drive the transformation of technology into tangible outcomes that benefit patients around the world.
In China, Medtronic has established a full value chain system encompassing R&D, manufacturing, commercialization, digitalization, and ecosystem collaboration over its 36 years of operation. By integrating local innovation with global resources, it continuously drives the upgrading of China's medical industry and the integrated development of global medical technology.